TrialThe Journal of infection2023

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.

Xinxue Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.